论文信息 - Treatment of a pediatric patient with MET‐amplified signet ring cell adenocarcinoma of the stomach with crizotinib

Treatment of a pediatric patient with MET‐amplified signet ring cell adenocarcinoma of the stomach with crizotinib

Signet ring cell adenocarcinoma (SRCA) of the stomach is an aggressive form of gastric cancer that correlates with an advanced disease stage and poor overall survival in pediatric patients.1–3 Herein, we report a case of stage IV SRCA of the stomach with mesenchymal epithelial transition (MET) amplification that responded to crizotinib, a dual anaplastic lymphoma receptor tyrosine kinase (ALK)/MET inhibitor, and conduct a literature review.

D. Berg | Shakoora A Sabree | Mariko Sato

[1] E. Beierle,et al. Colorectal carcinoma in pediatric patients: A comparison with adult tumors, treatment and outcomes from the National Cancer Database. , 2016, Journal of pediatric surgery.

[2] Anne Berger,et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. , 2015, World journal of gastroenterology.

[3] G. Varadhachary,et al. Gastric adenocarcinoma in children and adolescents , 2011, Pediatric blood & cancer.

[4] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[5] J. Ajani,et al. Treatment issues in pediatric gastric adenocarcinoma. , 2004, Journal of pediatric surgery.

[6] Hong Nguyen,et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. , 2004, Archives of pathology & laboratory medicine.